JAVIER GÓMEZ-TABALES

Dr. JAVIER GÓMEZ-TABALES


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2022 in European Journal of Clinical Investigation
Verified
Journal Article
Open access
EMELENA GARCIA MARTIN
ELENA GARCIA MARTIN
PPPau Pastor
Pau Pastor
JGJAVIER GÓMEZ-TABALES
JAVIER GÓMEZ-TABALES
HAHortensia Alonso-Navarro
Hortensia Alonso-Navarro
IAIgnacio Alvarez
Ignacio Alvarez
Felix Javier Jiménez JiménezFelix Javier Jiménez Jiménez
Felix Javier Jiménez Jiménez
Background/Objectives: Several recent studies suggest a possible role of lymphocyte activation 3 (LAG3) protein. LAG3 can behave as an α‐synuclein ligand, and serum and cerebrospinal fluid‐soluble LAG3 levels have been proposed as a marker of Parkinson's disease (PD). In this study, we aimed to investigate whether there is an association between 3 common single‐nucleotide variations (SNVs) in the LAG3 gene and its closely related CD4 molecule gene and the risk of PD in a Caucasian Spanish population. Two of them have been previously associated with the risk of PD in Chinese females.Methods: We analysed genotypes and allele frequencies for CD4 rs1922452, CD4 951818 and LAG3 rs870849 SNVs, by using specifically designed TaqMan assays, in a cohort composed of 629 PD patients and 865 age‐ and gender‐matched healthy controls.Results: The frequencies of the CD4 rs1922452 A/A genotype, according to the dominant and recessive genetic models, and of the CD4 rs1922452/A allelic variant were significantly lower, and the frequencies of the CD4 rs951818 A/A genotype, according to the dominant genetic model, and of the CD4 rs951818/A allele, were significantly higher in PD patients than in controls. The differences were not significant after stratifying by sex. These two SNVs showed strong linkage. Regression models showed a lack of relation between the 3 SNVs studied and the age at onset of PD.Conclusions: These data suggest a possible role of CD4 rs1922452 and CD4 rs951818 polymorphisms in the risk of PD.

Verified
Journal Article
Open access
PDF file
MAMariola Cerezo Arias
Mariola Cerezo Arias
JGJAVIER GÓMEZ-TABALES
JAVIER GÓMEZ-TABALES
MAManuel Martí Antonio
Manuel Martí Antonio
EMELENA GARCIA MARTIN
ELENA GARCIA MARTIN
Jose AgundezJose Agundez
Jose Agundez
Acetaminophen (paracetamol) is a widely used drug that causes adverse drug events that are often dose-dependent and related to plasma drug concentrations. Acetaminophen metabolism strongly depends on UGT1A enzymes. We aimed to investigate putative factors influencing acetaminophen pharmacokinetics. We analyzed acetaminophen pharmacokinetics after intravenous administration in 186 individuals, and we determined the effect of sex; body mass index (BMI); previous and concomitant therapy with UGT1A substrates, inhibitors, and inducers; as well as common variations in the genes coding for UGT1A1, UGT1A6, and UGT1A9. We identified sex and UGT1A6 genetic variants as major factors influencing acetaminophen pharmacokinetics, with women showing lower clearance (p < 0.001) and higher area under the plasma drug concentration-time curve (AUC) values than men (p < 0.001). UGT1A6 genetic variants were related to decreased acetaminophen biodisposition. Individuals who were homozygous or double-heterozygous for variant UGT1A6 alleles showed a 22.5% increase in t1/2 values and a 22.8 increase in drug exposure (p < 0.001, and 0.006, respectively) after correction by sex. The effect is related to the UGT1A6*2 and UGT1A6*4 variant alleles, whereas no effect of UGT1A6*3 and UGT1A9*3 alleles, BMI, or drug–drug interaction was identified in this study. We conclude that sex and UGT1A6 variants determine acetaminophen pharmacokinetics, thus providing evidence to eventually developing pharmacogenomics procedures and recommendations for acetaminophen use.

Verified
Journal Article
Open access
PDF file
EMELENA GARCIA MARTIN
ELENA GARCIA MARTIN
Jose AgundezJose Agundez
Jose Agundez
JGJAVIER GÓMEZ-TABALES
JAVIER GÓMEZ-TABALES
JBJulián Benito-León
Julián Benito-León
JPJorge Millán Pascual
Jorge Millán Pascual
Felix Javier Jiménez JiménezFelix Javier Jiménez Jiménez
Felix Javier Jiménez Jiménez
Several recent works have raised the possibility of the contribution of the lymphocyte activation gene 3 (LAG3) protein in the inflammatory processes of multiple sclerosis (MS). Results of studies on the possible association between LAG3 gene variants and the risk of MS have been inconclusive. In this study, we tried to show the possible association between the most common single nucleotide variants (SNVs) in the CD4 and LAG3 genes (these two genes are closely related) and the risk of MS in the Caucasian Spanish population. We studied the genotypes and allelic variants CD4 rs1922452, CD4 rs951818, and LAG3 rs870849 in 300 patients diagnosed with MS and 400 healthy patients using specific TaqMan-based qPCR assays. We analyzed the possible influence of the genotype frequency on age at the onset of MS, the severity of MS, clinical evolutive subtypes of MS, and the HLADRB1*1501 genotype. The frequencies of the CD4 rs1922452, CD4 rs951818, and LAG3 rs870849 genotypes and allelic variants were not associated with the risk of MS and were unrelated to gender, age at onset and severity of MS, the clinical subtype of MS, and HLADRB1*1501 genotype. The results of the current study showed a lack of association between the CD4 rs1922452, CD4 rs951818, and LAG3 rs870849 SNVs and the risk of developing MS in the Caucasian Spanish population.

Verified
Journal Article
Open access
PDF file
Felix Javier Jiménez JiménezFelix Javier Jiménez Jiménez
Felix Javier Jiménez Jiménez
JGJAVIER GÓMEZ-TABALES
JAVIER GÓMEZ-TABALES
HAHortensia Alonso-Navarro
Hortensia Alonso-Navarro
CRChristopher Rodríguez
Christopher Rodríguez
LTLaura Turpín-Fenoll
Laura Turpín-Fenoll
Jose AgundezJose Agundez
Jose Agundez
According to several studies, inflammatory factors could be related to the pathogenesis of idiopathic restless legs syndrome (RLS). In addition, RLS and Parkinson’s disease (PD) have shown a possible relationship, and recent studies have shown an association between CD4 rs1922452 and CD4 rs951818 single nucleotide variants (SNVs) and the risk for PD. For these reasons, we investigated the possible association between common variants in the LAG3/CD4 genes (which encoded proteins involved in inflammatory and autoimmune responses) and the risk for RLS in a Caucasian Spanish population. We assessed the frequencies of CD4 rs1922452, CD4 rs951818, and LAG3 rs870849 genotypes and allelic variants in 285 patients with idiopathic RLS and 350 healthy controls using a specific TaqMan-based qPCR assay. We also analyzed the possible influence of the genotypes’ frequencies on several variables, including age at onset of RLS, gender, family history of RLS, and response to drugs commonly used in the treatment of RLS. We found a lack of association between the frequencies of genotypes and allelic variants of the 3 SNVs studied and the risk of RLS, and a weak though significant association between the CD4 rs1922452 GG genotype and an older age at onset of RLS. With the exception of this association, our findings suggest that common SNVs in the CD4/LAG3 genes are not associated with the risk of developing idiopathic RLS in Caucasian Spanish people.

4 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
EMELENA GARCIA MARTIN
ELENA GARCIA MARTIN
JGJAVIER GÓMEZ-TABALES
JAVIER GÓMEZ-TABALES
Jose AgundezJose Agundez
Jose Agundez
JBJulián Benito-León
Julián Benito-León
JPJorge Millán Pascual
Jorge Millán Pascual
Felix Javier Jiménez JiménezFelix Javier Jiménez Jiménez
Felix Javier Jiménez Jiménez
Objectives: Several lines of evidence point to a potential involvement of oxidative stress in the pathophysiology of multiple sclerosis (MS). Superoxide dismutase isoenzymes 1 and 2 (SOD1 and SOD2) and catalase (CAT) are key components of the enzymatic antioxidant defense system. Consequently, genetic variation in the genes encoding these enzymes may influence susceptibility to MS. However, previous studies examining the relationship between SOD1, SOD2, and CAT variants and MS susceptibility have yielded inconsistent findings. The present study aimed to investigate whether two common single-nucleotide variants (SNVs) in CAT and SOD2 are associated with MS risk in a Caucasian Spanish population. Methods: We investigated the CAT rs1001179 and SOD2 rs4880 variants in 300 patients with MS and 400 healthy controls using allele-specific TaqMan quantitative PCR assays. We further examined whether these variants were related to relevant clinical characteristics, including age at disease onset, disease severity, and clinical course/subtype. Results: Neither the genotype nor allele distributions of CAT rs1001179 and SOD2 rs4880 differed significantly between patients with MS and healthy controls. Furthermore, no significant relationships were observed between either variant and sex, age at disease onset, disease severity, or clinical MS subtype. Conclusions: The present study did not detect significant associations between the CAT rs1001179 or SOD2 rs4880 variants and MS susceptibility in the Caucasian Spanish population. Similarly, no significant associations were detected between these variants and the clinical characteristics evaluated. However, smaller genetic effects cannot be excluded.

15 November 2026 in British Journal of Pharmacology
Verified
Journal Article
Open access
JGJesús Miguel García‐Menaya
Jesús Miguel García‐Menaya
JGJAVIER GÓMEZ-TABALES
JAVIER GÓMEZ-TABALES
SNSofía Ladera Navarro
Sofía Ladera Navarro
MAManuel Martí Antonio
Manuel Martí Antonio
NBNatalia Blanca‐López
Natalia Blanca‐López
PPPedro Ayuso Parejo
Pedro Ayuso Parejo
Background and Purpose: Nonsteroidal anti‐inflammatory drugs (NSAIDs) are a leading cause of drug hypersensitivity reactions (HRs), but genetic determinants of individual susceptibility remain unclear. Here, we identified genetic variants in redox‐ and immune‐related pathways associated with cross‐reactive NSAID hypersensitivity (CR‐NSAID) and single‐NSAID–induced urticaria/angioedema/anaphylaxis (SNIUAA) and to characterize their functional relevance. Experimental Approach: A multicentre prospective case–control study was conducted in Spanish individuals of European ancestry, including patients with confirmed NSAID hypersensitivity and NSAID‐tolerant individuals. Single nucleotide variants (SNVs) in redox‐ and immune‐related genes were genotyped using a two‐stage discovery and independent replication design. SNVs showing significant associations were functionally evaluated by measuring serum glutathione S‐transferase (GST), superoxide dismutase (SOD) and aldo‐keto reductase (AKR) activities according to genotype. Key Results: GSTM5 rs11101989 and GSTZ1 haplotype (rs1046428, rs7975, rs7972) associated with increased susceptibility to CR‐NSAID. Functional analyses demonstrated that carriers of the GSTM5 rs11101989 CC genotype had significantly reduced total serum GST activity. In SNIUAA, SOD1 variants (rs2070424 and rs2833483) associated with increased susceptibility and reduced serum SOD activity. Additionally, AKR1C3 rs34186955 increased susceptibility, whereas AKR1C3 rs12529 and IL4R rs1805016 associated with decreased susceptibility. Integration of genetic and functional data supported involvement of redox‐related pathways in distinct NSAID hypersensitivity phenotypes and identified GSTM5 and SOD1 variants as candidate genetic susceptibility markers. Conclusions and Implications: Genetic variability in redox‐related and immune‐regulatory pathways contributed to susceptibility to cross‐reactive and selective NSAID hypersensitivity. These findings support further validation of biomarker‐based strategies for personalized risk assessment and safer NSAID prescribing. Further validation in independent populations is required.